Description—- Pasireotide
Pasireotide is a somatostatin analog with a cyclic hexapeptide structure. Pasireotide as the main component of the drug is suitable for the treatment of adult patients with Cushing’s disease who have not undergone pituitary surgery or have not been cured by surgery. Compared with octreotide, pasireotide has a longer half-life, can bind to more receptors, inhibit pancreatic secretion, inhibit the activity of intestinal proteolytic enzymes, and reduce pancreatic postoperative complications through these mechanisms.
Specifications—- Pasireotide
| English Name: Pasireotide | |
| Sequence: Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl] |
|
| CAS: 396091-73-9 | Assay:98%+ |
| Molecular weight: 1047.21g/mol | Molecular formula: C58H66N10O9 |
| Appearance: White powder | Remarks: Only for research, not for human |
| Packing specifications (powder): 100mg, 1g, 10g, 100g,1kg or at customers request | Storage conditions: 2~8 °C |
Our Advantages—- Pasireotide
Professional peptide supplier
High purity custom peptide
Competitive price
